These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 30905548)

  • 21. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
    Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
    Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical treatment for cholangiocarcinoma.
    Adeva J; Sangro B; Salati M; Edeline J; La Casta A; Bittoni A; Berardi R; Bruix J; Valle JW
    Liver Int; 2019 May; 39 Suppl 1():123-142. PubMed ID: 30892822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current and emerging therapies for advanced biliary tract cancers.
    Kam AE; Masood A; Shroff RT
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies.
    Alsina M; Moehler M; Lorenzen S
    Oncol Res Treat; 2018; 41(5):266-271. PubMed ID: 29705786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infigratinib in patients with advanced cholangiocarcinoma with
    Makawita S; K Abou-Alfa G; Roychowdhury S; Sadeghi S; Borbath I; Goyal L; Cohn A; Lamarca A; Oh DY; Macarulla T; T Shroff R; Howland M; Li A; Cho T; Pande A; Javle M
    Future Oncol; 2020 Oct; 16(30):2375-2384. PubMed ID: 32580579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
    I Ilyas S; Borad MJ; Patel T; Gores GJ
    Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.
    Borger DR; Zhu AX
    Expert Rev Anticancer Ther; 2012 May; 12(5):543-6. PubMed ID: 22594888
    [No Abstract]   [Full Text] [Related]  

  • 29. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
    Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
    Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholangiocarcinoma: investigations into pathway-targeted therapies.
    Ntanasis-Stathopoulos I; Tsilimigras DI; Gavriatopoulou M; Schizas D; Pawlik TM
    Expert Rev Anticancer Ther; 2020 Sep; 20(9):765-773. PubMed ID: 32757962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
    Brown ZJ; Ruff SM; Pawlik TM
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
    J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Medical management of cholangiocarcinomas in 2015].
    Marret G; Neuzillet C; Rousseau B; Tournigand C
    Bull Cancer; 2016 Apr; 103(4):389-99. PubMed ID: 26922666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
    Jensen LH; Jakobsen A
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
    Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
    PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.
    Blair AB; Murphy A
    Curr Probl Cancer; 2018; 42(1):49-58. PubMed ID: 29501212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets.
    Tariq NU; Vogel A; McNamara MG; Valle JW
    Oncol Res Treat; 2018; 41(5):298-304. PubMed ID: 29705791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab.
    Naganuma A; Sakuda T; Murakami T; Aihara K; Watanuki Y; Suzuki Y; Shibasaki E; Masuda T; Uehara S; Yasuoka H; Hoshino T; Kudo T; Ishihara H; Ogawa T; Kitamoto Y; Ogawa A
    Intern Med; 2020 Sep; 59(18):2261-2267. PubMed ID: 32536644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mismatch Repair Protein Deficiency/Microsatellite Instability Is Rare in Cholangiocarcinomas and Associated With Distinctive Morphologies.
    Ju JY; Dibbern ME; Mahadevan MS; Fan J; Kunk PR; Stelow EB
    Am J Clin Pathol; 2020 Apr; 153(5):598-604. PubMed ID: 31844887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.